{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:14:27Z","timestamp":1794014067318,"version":"4.8.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Perugia (IT), Fondo di finanziamento della ricerca di base del Dipartimento di Scienze Chirurgiche e Biomediche","award":["Year 2015"],"award-info":[{"award-number":["Year 2015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>Fasting blood homocysteine is increased in PCOS women and is involved in several of its co-morbidities including cardiovascular disease and infertility. Corrective interventions based on the administration of supra-physiologic doses of folic acid work to a low extent. We aimed to test an alternative approach.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This was a prospective, randomized, parallel group, open label, controlled versus no treatment clinical study. PCOS women aged\u2009&gt;\u200918, free from systemic diseases and from pharmacological treatments were randomized with a 2:1 ratio for treatment with activated micronutrients in support to the carbon cycle (Impryl, Parthenogen, Switzerland\u2014<jats:italic>n<\/jats:italic>\u2009=\u200922) or no treatment (<jats:italic>n<\/jats:italic>\u2009=\u200910) and followed-up for 3\u00a0months. Fasting blood homocysteine, AMH, testosterone, SHBGs, and the resulting FTI were tested before and at the end of the follow-up.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The mean baseline fasting blood homocysteine was above the normal limit of 12 \u03bcMol\/L and inversely correlated with SHBG. AMH was also increased, whereas testosterone, SHBG, and FTI were within the normal limit. The treatment achieved a significant reduction of homocysteine, that did not change in the control group, independently of the starting value. The treatment also caused an increase of AMH and a decrease of SHBGs only in the subgroup with a normal homocysteine at baseline.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In PCOS ladies, blood homocysteine is increased and inversely correlated with the SHBGs. Physiologic amounts of activated micronutrients in support to the carbon cycle achieve a reduction virtually in all exposed patients. Whether this is of clinical benefit remains to be established.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s40618-019-01163-x","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T10:20:31Z","timestamp":1576491631000},"page":"779-786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Micronutrients in support to the one carbon cycle for the modulation of blood fasting homocysteine in PCOS women"],"prefix":"10.1007","volume":"43","author":[{"given":"N.","family":"Schiuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bartolotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0676-7929","authenticated-orcid":false,"given":"M.","family":"Dattilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8404-2918","authenticated-orcid":false,"given":"V.","family":"Bini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Aglietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Renga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-0962","authenticated-orcid":false,"given":"A.","family":"Favilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4532-3519","authenticated-orcid":false,"given":"A.","family":"Falorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gerli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"key":"1163_CR1","first-page":"1","volume":"6","author":"SM Sirmans","year":"2014","unstructured":"Sirmans SM, Pate KA (2014) Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 6:1\u201313","journal-title":"Clin Epidemiol"},{"issue":"3","key":"1163_CR2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/humupd\/dms059","volume":"19","author":"M Murri","year":"2013","unstructured":"Murri M, Luque-Ram\u0131rez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale H (2013) Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update 19(3):268\u2013288","journal-title":"Hum Reprod Update"},{"issue":"45","key":"1163_CR3","doi-asserted-by":"publisher","first-page":"42912","DOI":"10.1074\/jbc.M206588200","volume":"277","author":"S Ratnam","year":"2002","unstructured":"Ratnam S, Maclean KN, Jacobs RL, Brosnan ME, Kraus JP, Brosnan JT (2002) Hormonal regulation of cystathionine beta-synthase expression in liver. J Biol Chem 277(45):42912\u201342918","journal-title":"J Biol Chem"},{"issue":"6","key":"1163_CR4","doi-asserted-by":"publisher","first-page":"e0157389","DOI":"10.1371\/journal.pone.0157389","volume":"11","author":"Y Meng","year":"2016","unstructured":"Meng Y, Chen X, Peng Z, Liu X, Sun Y, Dai S (2016) Association between high serum homocysteine levels and biochemical characteristics in women with polycystic ovarian syndrome: a systematic review and meta-analysis. PLoS One 11(6):e0157389","journal-title":"PLoS One"},{"issue":"2","key":"1163_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.2337\/dc09-1516","volume":"33","author":"S Palomba","year":"2010","unstructured":"Palomba S, Falbo A, Giallauria F, Russo T, Tolino A, Zullo F, Colao A, Iorio F (2010) Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. Diabetes Care 33(2):246\u2013251","journal-title":"Diabetes Care"},{"issue":"2","key":"1163_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4103\/jhrs.JHRS_74_16","volume":"10","author":"S Esmaeilzadeh","year":"2017","unstructured":"Esmaeilzadeh S, Maryam Gholinezhad-Chari M, Reza Ghadimi R (2017) The effect of metformin treatment on the serum levels of homocysteine, folic acid, and vitamin B12 in patients with polycystic ovary syndrome. J Hum Reprod Sci 10(2):95\u2013101","journal-title":"J Hum Reprod Sci"},{"key":"1163_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12986-017-0233-z","volume":"14","author":"A Kumar","year":"2017","unstructured":"Kumar A, Palfrey HA, Pathak R, Kadowitz PJ, Gettys TW, Murthy SN (2017) The metabolism and significance of homocysteine in nutrition and health. Nutr Metab 14:78","journal-title":"Nutr Metab"},{"issue":"3","key":"1163_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/humupd\/dml063","volume":"13","author":"T Forges","year":"2007","unstructured":"Forges T, Monnier-Barbarino P, Alberto JM, Gu\u00e9ant-Rodriguez RM, Daval JL, Gu\u00e9ant JL (2007) Impact of folate and homocysteine metabolism on human reproductive health. Hum Reprod Update 13(3):225\u2013238","journal-title":"Hum Reprod Update"},{"issue":"9","key":"1163_CR9","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1093\/humrep\/dep069","volume":"24","author":"B Berker","year":"2009","unstructured":"Berker B, Kaya C, Aytac R, Sat\u0131roglu H (2009) Homocysteine concentrations in follicular fluid are associated with poor oocyte and embryo qualities in polycystic ovary syndrome patients undergoing assisted reproduction. Hum Reprod 24(9):2293\u20132302","journal-title":"Hum Reprod"},{"issue":"5","key":"1163_CR10","doi-asserted-by":"publisher","first-page":"e64446","DOI":"10.1371\/journal.pone.0064446","volume":"8","author":"P Chakraborty","year":"2013","unstructured":"Chakraborty P, Goswami SK, Rajani S, Sharma S, Kabir SN, Chakravarty B, Jana K (2013) Recurrent pregnancy loss in polycystic ovary syndrome: role of hyperhomocysteinemia and insulin resistance. PLoS One 8(5):e64446","journal-title":"PLoS One"},{"key":"1163_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12933-018-0680-5","volume":"17","author":"D Glintborg","year":"2018","unstructured":"Glintborg D, Rubin KH, Nybo M, Abrahamsen B, Andersen M (2018) Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. Cardiovasc Diabetol 17:37","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"1163_CR12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jpag.2016.03.004","volume":"29","author":"F Fruzzetti","year":"2016","unstructured":"Fruzzetti F, Ghiadoni L, Virdis A, De Negri F, Perini D, Bucci F, Giannarelli C, Gadducci A, Taddei S (2016) Adolescents with classical polycystic ovary syndrome have alterations in the surrogate markers of cardiovascular disease but not in the endothelial function. The possible benefits of metformin. Pediatr Adolesc Gynecol 29(5):489\u2013495","journal-title":"Pediatr Adolesc Gynecol"},{"issue":"11","key":"1163_CR13","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.4065\/83.11.1203","volume":"83","author":"LL Humphrey","year":"2008","unstructured":"Humphrey LL, Fu R, Rogers K, Freeman L, Helfand M (2008) Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 83(11):1203\u20131212","journal-title":"Mayo Clin Proc"},{"key":"1163_CR14","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s10815-016-0767-4","volume":"33","author":"M Dattilo","year":"2016","unstructured":"Dattilo M, D\u2019Amato G, Caroppo E, Menezo Y (2016) Improvement of gamete quality by stimulating and feeding the endogenous antioxidant system: mechanisms, clinical results, insights on gene-environment interactions and the role of diet. J Assist Reprod Genet 33:1633\u20131648","journal-title":"J Assist Reprod Genet"},{"issue":"9","key":"1163_CR15","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/oxfordjournals.aje.a010290","volume":"151","author":"L Botto","year":"2000","unstructured":"Botto L, Yang Q (2000) 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epiedemiol 151(9):862\u2013877","journal-title":"Am J Epiedemiol"},{"issue":"3","key":"1163_CR16","doi-asserted-by":"publisher","first-page":"e57917","DOI":"10.1371\/journal.pone.0057917","volume":"8","author":"B Yang","year":"2013","unstructured":"Yang B, Liu Y, Li Y, Fan S, Zhi X, Lu X, Wang D, Zheng Q, Wang Y, Wang Y, Sun G (2013) Geographical distribution of MTHFR C677T, A1298C and MTRR A66G Gene polymorphisms in China: findings from 15357 adults of han nationality. PLoS One 8(3):e57917","journal-title":"PLoS One"},{"issue":"1","key":"1163_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","volume":"19","author":"The Rotterdam ESHRE\/ASRM-sponsored PCOS consensus workshop group","year":"2004","unstructured":"The Rotterdam ESHRE\/ASRM-sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19(1):41\u201347","journal-title":"Hum Reprod"},{"issue":"8","key":"1163_CR18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.29252\/ijrm.14.8.495","volume":"14","author":"Z Eskandari","year":"2016","unstructured":"Eskandari Z, Sadrkhanlou R-A, Nejati V, Tizro G (2016) PCOS women show significantly higher homocysteine level, independent to glucose and E2 level. Int J Reprod BioMed 14(8):495\u2013500","journal-title":"Int J Reprod BioMed"},{"issue":"7","key":"1163_CR19","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/mnfr.201400033","volume":"58","author":"Z Asemi","year":"2014","unstructured":"Asemi Z, Karamali M, Esmailzadeh A (2014) Metabolic response to folate supplementation in overweight women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Mol Nutr Food Res 58(7):1465\u20131473","journal-title":"Mol Nutr Food Res"},{"issue":"36","key":"1163_CR20","doi-asserted-by":"publisher","first-page":"15424","DOI":"10.1073\/pnas.0902072106","volume":"106","author":"SW Bailey","year":"2009","unstructured":"Bailey SW, Ayling JE (2009) The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake. PNAS 106(36):15424\u201315429","journal-title":"PNAS"},{"issue":"7","key":"1163_CR21","doi-asserted-by":"crossref","first-page":"2050313X1985043","DOI":"10.1177\/2050313X19850435","volume":"17","author":"D Cornet","year":"2019","unstructured":"Cornet D, Clement A, Clement B, Menezo Y (2019) High doses of folic acid induce a pseudo-methylenetetrahydrofolate syndrome. SAGE Open Med Case Rep 17(7):2050313X19850435.35","journal-title":"SAGE Open Med Case Rep"},{"key":"1163_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/nyas.13499","volume":"1414","author":"MS Field","year":"2018","unstructured":"Field MS, Stover PJ (2018) Safety of folic acid. Ann N Y Acad Sci 1414:59\u201371","journal-title":"Ann N Y Acad Sci"},{"key":"1163_CR23","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1038\/s41598-018-22191-2","volume":"8","author":"SW Bailey","year":"2018","unstructured":"Bailey SW, Ayling JE (2018) The pharmacokinetic advantage of 5-methyltetrahydrofolate for minimization of the risk for birth defects. Sci Rep 8:4096","journal-title":"Sci Rep"},{"issue":"6","key":"1163_CR24","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/humrep\/deh825","volume":"20","author":"EB Kilicdag","year":"2005","unstructured":"Kilicdag EB, Bagis T, Tarim E, Aslan E, Erkanli S, Simsek E, Haydardedeoglu B, Kuscu E (2005) Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial. Hum Reprod 20(6):1521\u20131528","journal-title":"Hum Reprod"},{"issue":"10","key":"1163_CR25","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s40618-018-0832-1","volume":"41","author":"R Pasquali","year":"2018","unstructured":"Pasquali R, Gambineri A (2018) New perspectives on the definition and management of polycystic ovary syndrome. J Endocrinol Invest. 41(10):1123\u20131135","journal-title":"J Endocrinol Invest."},{"key":"1163_CR26","doi-asserted-by":"publisher","DOI":"10.1089\/biores-2017.0016","author":"E Silvestris","year":"2017","unstructured":"Silvestris E, Cohen M, Cornet D, Jacquesson-Fournols L, Clement P, Chouteau J, Schneider M, Besnard T, Menezo Y (2017) Supporting the one-carbon cycle restores ovarian reserve in subfertile women: absence of correlation with urinary bisphenol A concentration. BioResearch Open Access. https:\/\/doi.org\/10.1089\/biores-2017.0016","journal-title":"BioResearch Open Access"},{"issue":"5","key":"1163_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1210\/er.2015-1104","volume":"37","author":"RL Rosenfield","year":"2016","unstructured":"Rosenfield RL, Ehrmann DA (2016) The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev 37(5):467\u2013520","journal-title":"Endocr Rev"},{"issue":"1","key":"1163_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/19396368.2017.1410591","volume":"64","author":"R Deswal","year":"2018","unstructured":"Deswal R, Yadav A, Dang AS (2018) Sex hormone binding globulin - an important biomarker for predicting PCOS risk: a systematic review and meta-analysis. Syst Biol Reprod Med 64(1):12\u201324","journal-title":"Syst Biol Reprod Med"},{"key":"1163_CR29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1530\/EJE-07-0203","volume":"157","author":"N Kajaia","year":"2007","unstructured":"Kajaia N, Binder H, Dittrich R, Oppelt PG, Flor B, Cupisti S, Beckmann MW, Mueller A (2007) Low sex hormone-binding globulin as a predictive marker for insulin resistance in women with hyperandrogenic syndrome. Eur J Endocrinol 157:499\u2013507","journal-title":"Eur J Endocrinol"},{"key":"1163_CR30","doi-asserted-by":"publisher","first-page":"19436","DOI":"10.1038\/srep19436","volume":"6","author":"L Jia","year":"2016","unstructured":"Jia L, Li J, He B, Jia Y, Niu Y, Wang C, Zhao R (2016) Abnormally activated one-carbon metabolic pathway is associated with mtDNA hypermethylation and mitochondrial malfunction in the oocytes of polycystic gilt ovaries. Sci Rep 6:19436","journal-title":"Sci Rep"},{"key":"1163_CR31","doi-asserted-by":"publisher","first-page":"R27","DOI":"10.1530\/REP-18-0449","volume":"158","author":"ER V\u00e1zquez-Mart\u00ednez","year":"2019","unstructured":"V\u00e1zquez-Mart\u00ednez ER, G\u00f3mez-Viais YI, Garc\u00eda-G\u00f3mez E, Reyes-Mayoral C, Reyes-Mu\u00f1oz E, Camacho-Arroyo I, Cerb\u00f3n M (2019) DNA methylation in the pathogenesis of polycystic ovary syndrome. Reproduction 158: R27\u2013R40","journal-title":"Reproduction"},{"issue":"2","key":"1163_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3132\/dvdr.2007.033","volume":"4","author":"A Wierzbicki","year":"2007","unstructured":"Wierzbicki A (2007) Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res 4(2):143\u2013150","journal-title":"Diab Vasc Dis Res"},{"key":"1163_CR33","doi-asserted-by":"publisher","first-page":"R238","DOI":"10.1530\/EC-18-0129","volume":"7","author":"KB Studen","year":"2018","unstructured":"Studen KB, Pfeifer M (2018) Cardiometabolic risk in polycystic ovary syndrome. Endocr Connect 7:R238\u2013R251","journal-title":"Endocr Connect"},{"key":"1163_CR34","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jama.291.5.565","volume":"291","author":"F James","year":"2004","unstructured":"James F, Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. JAMA 291:565\u2013575","journal-title":"JAMA"},{"issue":"15","key":"1163_CR35","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1056\/NEJMoa055227","volume":"354","author":"KH B\u00f8naa","year":"2006","unstructured":"B\u00f8naa KH, Inger Nj\u00f8lstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K, for the NORVIT Trial Investigators (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354(15):1578\u20131588","journal-title":"N Engl J Med"},{"issue":"12","key":"1163_CR36","doi-asserted-by":"publisher","first-page":"E798","DOI":"10.3390\/nu8120798","volume":"8","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, Li S, Li L, Li Q, Ren K, Sun X, Li J (2016) Metformin treatment and homocysteine: a systematic review and meta-analysis of randomized controlled trials. Nutrients 8(12):E798","journal-title":"Nutrients"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01163-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-019-01163-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01163-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T01:05:01Z","timestamp":1607994301000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-019-01163-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,16]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["1163"],"URL":"https:\/\/doi.org\/10.1007\/s40618-019-01163-x","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,16]]},"assertion":[{"value":"21 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M. D. reports personal fees from Parthenogen SAGL, outside the submitted work; in addition, M. D. is inventor of the pending patent \u2018Dietary supplementation to achieve oxy-redox homeostasis and epigenetic stability\u2019. The other authors have no competing interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The research was carried out according to the principles of the Declaration of Helsinki, in accordance with the relevant guidelines and ethical regulations in research involving human participants. The study was approved by the Ethical Committee of Aziende Sanitarie della Regione Umbria (CEAS).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Each enrolled subject delivered a written informed consent for participation in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}